发明名称 |
Oncolytic vaccinia virus cancer therapy |
摘要 |
Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×108 infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor. |
申请公布号 |
US9226977(B2) |
申请公布日期 |
2016.01.05 |
申请号 |
US201514656397 |
申请日期 |
2015.03.12 |
申请人 |
SillaJen Biotherapeutics, Inc. |
发明人 |
Kirn David |
分类号 |
A61K48/00;A61K9/00;A61K38/19;A61K45/06;A61K35/768 |
主分类号 |
A61K48/00 |
代理机构 |
Morgan, Lewis & Bockius LLP |
代理人 |
Morgan, Lewis & Bockius LLP |
主权项 |
1. A method of inducing oncolysis in a human subject having a tumor comprising administering to said subject one or more single doses of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified TK-deficient, human GM-CSF-expressing, replication-competent vaccinia virus vector wherein said single dose comprises 1×109 pfu to 1×1010 pfu, and wherein said administering comprises injection into the tumor mass, whereby oncolysis is induced in said tumor and in at least one tumor that is not injected with the virus. |
地址 |
San Francisco CA US |